Resnick M I, Roehrborn C G
Department of Urology, Case Medical Center, Cleveland, OH 44106, USA.
Prostate Cancer Prostatic Dis. 2007;10(2):155-9. doi: 10.1038/sj.pcan.4500925. Epub 2007 Jan 9.
This randomized, double-blind, placebo-controlled study was conducted to investigate whether alfuzosin 10 mg once daily improves the maximum flow rate (Q(max)) and lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH) after 1 week and 1 month of treatment. A total of 372 men aged > or = 50 years with symptomatic BPH received alfuzosin or placebo for 28 days. Q(max) increased significantly from baseline at day 8 with alfuzosin (P<0.001 versus placebo); this improvement was evident within 24 h after the first dose and was maintained at day 29. LUTS improved from baseline with alfuzosin at day 8 (P=0.07 versus placebo) and day 29 (P=0.003 versus placebo). Alfuzosin 10 mg once daily exhibits a rapid onset of action, with improvements in Q(max) and LUTS maintained through 1 month of treatment.
本随机、双盲、安慰剂对照研究旨在调查每日一次服用10毫克阿夫唑嗪，在治疗1周和1个月后是否能改善良性前列腺增生（BPH）患者的最大尿流率（Q(max)）和下尿路症状（LUTS）。共有372名年龄≥50岁的有症状BPH男性患者接受阿夫唑嗪或安慰剂治疗28天。服用阿夫唑嗪后，第8天时Q(max)较基线水平显著升高（与安慰剂相比，P<0.001）；首次给药后24小时内这种改善就很明显，并在第29天维持。第8天（与安慰剂相比，P=0.07）和第29天（与安慰剂相比，P=0.003）时，服用阿夫唑嗪的患者LUTS较基线水平有所改善。每日一次服用10毫克阿夫唑嗪起效迅速，治疗1个月内Q(max)和LUTS持续改善。
